- Current report filing (8-K)
December 15 2009 - 4:12PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13
or 15(d) of
the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported):
December 15, 2009
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
|
0-19700
|
|
33-0266089
|
(State or Other
Jurisdiction of
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
Incorporation)
|
|
|
|
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8K is
intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a12 under the Exchange Act (17 CFR 240.14a12)
o
Pre
commencement communications
pursuant to Rule 14d2(b) under the Exchange Act (17 CFR 240.14d2(b))
o
Precommencement communications pursuant to Rule 13e4(c) under
the Exchange Act (17 CRF 240.13e4(c))
Item 8.01. Other Events.
On December 15, 2009, Amylin
Pharmaceuticals, Inc. (Amylin) issued a press release announcing
positive results from DURATION-5, a head-to-head study comparing exenatide once
weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection
taken twice daily, in patients with type 2 diabetes. A copy of the press release is attached as Exhibit 99.1
and is incorporated herein by reference.
Item 9.01. Financial Statements
and Exhibits.
(d) Exhibits.
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin on December 15, 2009.
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
Dated:
|
December 15,
2009
|
By:
|
/s/ LLOYD A.
ROWLAND
|
|
|
|
Lloyd A. Rowland
|
|
|
|
Vice
President, Governance and Compliance, and Secretary
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Press release
issued by Amylin on December 15, 2009.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Sep 2024 to Oct 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Oct 2023 to Oct 2024